Premium
Characterization of WR‐1065 absorption in the rat small intestine
Author(s) -
Geary R. S.,
Swynnerton N. F.,
Timmons S. F.,
Mangold D. J.
Publication year - 1991
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510120405
Subject(s) - absorption (acoustics) , chemistry , small intestine , perfusion , metabolism , pharmacokinetics , biochemistry , pharmacology , medicine , biology , materials science , composite material
A circulating in situ rat small intestine absorption model was used to study the lumenal metabolism and absorption of [ 14 ]WR‐1065. WR‐1065 was found to be more tissue reactive and toxic than its phosphorylated form, ethiofos, at equimolar perfusate concentrations. The disappearance profiles of the radiolabeled drug and free WR‐1065 indicate that WR‐1065 is extensively metabolized in the intestinal lumen prior to absorption. Coadministration of disodium ethylenediaminetetraacetic acid enhances the absorption of the free thiol although not to the same extent as seen with ethiofos. Perfusion of WR‐1065 in citrate buffer decreased lumenal degradation of the drug but resulted in decreased absorption. The total material converted to WR‐1065 portal blood profiles following ethiofos and WR‐1065 perfusion were altered possibly due to distribution and metabolism differences. This study coupled with earlier work completed on ethiofos have increased our understanding of the significant barriers to absorption observed following oral administration of these compounds.